Trails Edge Capital Partners, LP
Regulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 98.9%; sector active share 90.1% against the combined 13F book's sector weights.
Over time 3 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
35 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 99.2% | $624,561,875 |
| Financial Services | 0.8% | $5,350,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| IRD | Opus Genetics, Inc. | +2,243,658 | 2,743,658 | $11,276,434 | |
| IPSC | Century Therapeutics, Inc. | +1,684,976 | 4,134,969 | $10,130,674 | |
| DSGN | Design Therapeutics, Inc. | +1,149,269 | 2,001,282 | $28,958,550 | |
| IKT | Inhibikase Therapeutics, Inc. | +993,973 | 9,051,318 | $18,374,175 | |
| FDMT | 4D Molecular Therapeutics, Inc. | +925,000 | 2,227,917 | $29,631,296 | |
| SNDX | Syndax Pharmaceuticals Inc | +408,179 | 1,110,000 | $24,264,600 | |
| FTH | Faeth Therapeutics, Inc. | +390,335 | 515,335 | $12,883,375 | |
| IMCR | Immunocore Holdings plc | +380,637 | 1,063,234 | $33,757,679 | |
| LBRX | Lb Pharmaceuticals Inc | +203,660 | 1,523,022 | $49,429,679 | |
| SLGL | Sol-Gel Technologies Ltd. | +53,949 | 139,445 | $10,338,452 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | −170,000 | 1,573,220 | $38,166,317 | |
| RVMD | Revolution Medicines, Inc. | −129,250 | 115,750 | $21,677,660 | |
| MIRM | Mirum Pharmaceuticals, Inc. | −110,000 | 223,312 | $26,143,135 | |
| NGNE | Neurogene Inc. | −67,902 | 714,885 | $22,483,133 | |
| VTVT | vTv Therapeutics Inc. | −54,386 | 85,192 | $3,207,478 | |
| CYTK | Cytokinetics Inc | −11,911 | 288,089 | $24,542,301 | |
| CAMP | Camp4 Therapeutics Corp | −6,626 | 1,932,937 | $8,446,934 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| TRAX | First Tracks Biotherapeutics, Inc. | 1,514,000 | $30,461,680 | |
| BMRN | Biomarin Pharmaceutical Inc | 512,000 | $29,296,640 | |
| INSM | INSMED Inc | 230,331 | $24,557,891 | |
| KLRA | Kailera Therapeutics, Inc. | 984,786 | $21,694,835 | |
| INCY | Incyte Corp | 155,000 | $17,570,800 | |
| AVTX | Avalo Therapeutics, Inc. | 891,881 | $16,481,960 | |
| MLTX | MoonLake Immunotherapeutics | 750,000 | $14,602,500 | |
| AURA | Aura Biosciences, Inc. | 1,443,333 | $10,247,664 | |
| ALT | Altimmune, Inc. | 2,660,000 | $8,086,400 | |
| OKUR | OnKure Therapeutics, Inc. | 1,438,456 | $6,559,359 | |
| — | 273,181 | $5,805,096 | ||
| RACC | Research Alliance Corp III | 500,000 | $5,350,000 | |
| IMA | ImageneBio, Inc. | 282,004 | $1,663,823 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| LBRX |
Lb Pharmaceuticals Inc
Healthcare
|
Added | 1,523,022 | $49,429,679 | 7.85% | |
| NRIX |
Nurix Therapeutics, Inc.
Healthcare
|
Reduced | 1,573,220 | $38,166,317 | 6.06% | |
| IMCR |
Immunocore Holdings plc
Healthcare
|
Added | 1,063,234 | $33,757,679 | 5.36% | |
| TRAX |
First Tracks Biotherapeutics, Inc.
Healthcare
|
NEW | 1,514,000 | $30,461,680 | 4.84% | |
| FDMT |
4D Molecular Therapeutics, Inc.
Healthcare
|
Added | 2,227,917 | $29,631,296 | 4.70% | |
| BMRN |
Biomarin Pharmaceutical Inc
Healthcare
|
NEW | 512,000 | $29,296,640 | 4.65% | |
| DSGN |
Design Therapeutics, Inc.
Healthcare
|
Added | 2,001,282 | $28,958,550 | 4.60% | |
| XENE |
Xenon Pharmaceuticals Inc.
Healthcare
|
Reduced | 440,000 | $26,558,400 | 4.22% | |
| MIRM |
Mirum Pharmaceuticals, Inc.
Healthcare
|
Reduced | 223,312 | $26,143,135 | 4.15% | |
| INSM |
INSMED Inc
Healthcare
|
NEW | 230,331 | $24,557,891 | 3.90% | |
| CYTK |
Cytokinetics Inc
Healthcare
|
Reduced | 288,089 | $24,542,301 | 3.90% | |
| SNDX |
Syndax Pharmaceuticals Inc
Healthcare
|
Added | 1,110,000 | $24,264,600 | 3.85% | |
| NGNE |
Neurogene Inc.
Healthcare
|
Reduced | 714,885 | $22,483,133 | 3.57% | |
| KLRA |
Kailera Therapeutics, Inc.
Healthcare
|
NEW | 984,786 | $21,694,835 | 3.44% | |
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Reduced | 115,750 | $21,677,660 | 3.44% | |
| IKT |
Inhibikase Therapeutics, Inc.
Healthcare
|
Added | 9,051,318 | $18,374,175 | 2.92% | |
| INCY |
Incyte Corp
Healthcare
|
NEW | 155,000 | $17,570,800 | 2.79% | |
| AVTX |
Avalo Therapeutics, Inc.
Healthcare
|
NEW | 891,881 | $16,481,960 | 2.62% | |
| MLTX |
MoonLake Immunotherapeutics
Healthcare
|
NEW | 750,000 | $14,602,500 | 2.32% | |
| FTH |
Faeth Therapeutics, Inc.
Healthcare
|
Added | 515,335 | $12,883,375 | 2.05% | |
| XFOR |
X4 Pharmaceuticals, Inc
Healthcare
|
Held | 2,571,478 | $12,008,802 | 1.91% | |
| IRD |
Opus Genetics, Inc.
Healthcare
|
Added | 2,743,658 | $11,276,434 | 1.79% | |
| SLGL |
Sol-Gel Technologies Ltd.
Healthcare
|
Added | 139,445 | $10,338,452 | 1.64% | |
| AURA |
Aura Biosciences, Inc.
Healthcare
|
NEW | 1,443,333 | $10,247,664 | 1.63% | |
| IPSC |
Century Therapeutics, Inc.
Healthcare
|
Added | 4,134,969 | $10,130,674 | 1.61% | |
| IVA |
Inventiva S.A.
Healthcare
|
Held | 2,657,997 | $10,047,228 | 1.60% | |
| CAMP |
Camp4 Therapeutics Corp
Healthcare
|
Reduced | 1,932,937 | $8,446,934 | 1.34% | |
| ALT |
Altimmune, Inc.
Healthcare
|
NEW | 2,660,000 | $8,086,400 | 1.28% | |
| NERV |
Minerva Neurosciences, Inc.
Healthcare
|
Held | 1,419,000 | $7,875,450 | 1.25% | |
| PMN |
ProMIS Neurosciences Inc.
Healthcare
|
Held | 557,103 | $7,331,475 | 1.16% | |
| OKUR |
OnKure Therapeutics, Inc.
Healthcare
|
NEW | 1,438,456 | $6,559,359 | 1.04% | |
|
|
NEW | 273,181 | $5,805,096 | 0.92% | ||
| RACC |
Research Alliance Corp III
Financial Services
|
NEW | 500,000 | $5,350,000 | 0.85% | |
| VTVT |
vTv Therapeutics Inc.
Healthcare
|
Reduced | 85,192 | $3,207,478 | 0.51% | |
| IMA |
ImageneBio, Inc.
Healthcare
|
NEW | 282,004 | $1,663,823 | 0.26% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.